TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04852042

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mHealth
Description: Participants will receive 2-3 text messages daily. The messages will include information to promote healthy eating and physical activity.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mHealth
Description: Participants will receive 2-3 text messages daily. The messages will include information to promote healthy eating and physical activity.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CHW support
Description: The CHW will provide behavioral counseling to participants guided by a study website related to their healthy eating and physical activity goals.
Study: NCT06024850

Intervention type: OTHER
Intervention: Datas collected
Description: Datas collected by medical record: medical data (weight, height, smoking status, history) and socio-demographic data (age, occupation, type of injury) information, assessment of knee function before surgery, at 6 months and 1 year after surgery, magnetic resonance imaging (MRI) and radiological imaging at 1 year after surgery, results of the Iso-kinetic Muscle Assessment Test at 1 year after surgery to objectively determine the recovery of muscle function~The data collected will be used to perform a statistical analysis to evaluate the factors predicting a good long-term post-surgical evolution
Study: NCT05424666

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Harvesting method and Fat graft preparation method
Description: The procedure begins by identifying the areas where the fat will be collected Then the sample is collected by micro-incision using a fine suction cannula or during conventional liposuction. The fat cells are taken from an area of the body where there is a reserve (generally, in the abdomen, hips, knees, inner thighs, buttock) The collected fat cells are then subjected to a sterile centrifugation for a few minutes so as to separate the cells that will be injected (intact fat cells) from the elements that must not be injected (fat cells destroyed by the sample, non-fat cells such as than blood cells).~Injection of fat cells into the breasts The reinjection of fat (lipofilling) is performed using micro-cannulas allowing incisions of the order of 1-2 mm in different angles and in multiple directions so as to increase the contact area between the grafted cells and the recipient tissues allowing a good grip of the injection.
Study: NCT06523478

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intratonsillar immunotherapy (ITIT)
Description: During injection, the operator needs to gently shake the injection bottle about 20 times, the drug must be mixed to ensure the consistency of allergen concentration, and carefully check the patient's name and concentration on the bottle. Allergy extracts should not be injected intravenously, so the syringe will be aspirated to avoid inadvertent intravascular injection. Before each injection, after inserting the needle into the selected tonsil, before injecting the dose, the investigator will slightly pull the plunger of the syringe. If blood returns from the syringe, the syringe, and its contents will be discarded. The other tonsil will be selected and a new syringe will be prepared.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Subcutaneous immunotherapy (SCIT)
Description: Injection requires shaking bottle 20x to mix drug for consistency. Verify patient name \& concentration. Use 1 ml skin test syringe for deep subcutaneous injection at 45° angle, 1 cm into outer upper arm. Lift skin folds for deeper injection, avoid subcutaneous, muscular or intravascular. Inject slowly, 1 min for 1 ml. Avoid shallow injections which may cause local side effects. Alternate between left \& right arm for 5 min after injection for compression.
Study: NCT05098925

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Biological testing
Description: Blood sampling, microcapillary sampling, temperature monitoring, saliva testing, EHI questionnaire
Study: NCT05604222

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirabegron 50 MG
Description: Medication to treat overactive bladder

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirabegron 50 MG
Description: Medication to treat overactive bladder

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Behavioral Treatment for Insomnia
Description: A behavioral intervention for insomnia
Study: NCT05460117

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Radiofrecuency
Description: he use of 448kilohertz capacitive resistive monopolar radiofrequency as the focus of the treatment looking for improve the quality of the tissue is still to be explored.
Study: NCT05953246

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Neutral labels
Description: Participants view neutral labels (QR codes with and without neutral text) for menu items

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Numeric text-only sustainability labels
Description: Participants view labels with numeric text depicting the greenhouse gas emissions associated with production of the menu item

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Endorsement text-only sustainability labels
Description: Participants view labels using text to endorse menu items as having low environmental impact

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Endorsement icon-only sustainability labels
Description: Participants view labels using icons to endorse menu items as having low environmental impact
Study: NCT04796324

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixabepilone Injection
Description: Ixabepilone 40 mg/m2 is administered as a 3-h intravenous infusion Day 1 in a 3-week cycle
Study: NCT05782816

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin
Description: Low dose oxytocin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin
Description: High dose oxytocin
Study: NCT05954910

Intervention type: DRUG
Intervention: Polatuzumab Vedotin
Description: Polatuzumab vedotin will be administered at the discretion of the physician per local clinical practice and local labeling.

Intervention type: DRUG
Intervention: Polatuzumab Vedotin
Description: Polatuzumab vedotin will be administered at the discretion of the physician per local clinical practice and local labeling.

Intervention type: DRUG
Intervention: Polatuzumab Vedotin
Description: Polatuzumab vedotin will be administered at the discretion of the physician per local clinical practice and local labeling.
Study: NCT06537063

Intervention type: OTHER
Intervention: G4 DNAm test
Description: Detection of DNA methylation (DNAm) around G-quadruplex loci in cell-free DNA from blood.
Study: NCT05941520

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acolbifene Hydrochloride
Description: Given PO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biospecimen Collection
Description: Undergo collection of blood

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Mammography
Description: Undergo 3D mammography

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Random Periareolar Fine-Needle Aspiration
Description: Undergo RPFNA

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Random Periareolar Fine-Needle Aspiration
Description: Undergo RPFNA

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tamoxifen
Description: Given PO
Study: NCT06453083

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets will be dispensed to the participants for 6-days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Medrol
Description: Medrol tablets will be dispensed to the participants for 6-days.
Study: NCT05953246

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Endorsement text-plus-icon sustainability labels
Description: Participants view labels using text and icons to endorse menu items as having low environmental impact
Study: NCT05230108

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Advanced Triage
Description: Advanced triage is an intervention that allows the emergency nurse to resolve health problems of low clinical complexity. All actions are aimed at resolving a health problem based on a protocol previously agreed upon by a multidisciplinary team.
Study: NCT05039645

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Patient specific, clinician determined Intervention
Description: Data collected from the DFS device will be transmitted to a remote, cloud-based server for daily review using the SRI software. If a temperature difference of \>2.2°C between similar points on the left and right feet is identified for 2 consecutive scans, or visible signs of skin damage are observed, the site will be notified and sent a report containing the findings. Once notified the site will contact the patient by telephone and determine the best course of action based on standard practices (e.g. offloading, attending an appointment).
Study: NCT05808491

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: online resilience intervention
Description: online resilience intervention were presented in four 60-minute sections, once a week for four weeks embracing four sections
Study: NCT02645149

Intervention type: DRUG
Group type: OTHER
Intervention: Standard therapy or clinical trial
Description: Patients with BRAF V600 mutations detected by standard of care tumour testing will be treated with standard approved therapies or on clinical trials.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Matched targeted therapy
Description: Patients with tumour found to be non-V600 BRAF, BRAF wildtype and NRAS wildtype melanoma will have tumour tested further using the extended molecular testing platform designed for this project. Patients will first receive standard therapy(ies) for non-V600 BRAF, wildtype and NRAS wildtype melanoma until disease progression or intolerable drug toxicities. Followed by a targeted therapy matched to the genetic aberration detected in their tumour on NGS testing.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib and / or supportive care
Description: Patients with non-V600 BRAF, BRAF wildtype and NRAS wildtype melanoma for whom there is no actionable genetic aberration found on extended molecular testing, may receive trametinib (if not already administered as part of standard care) and/or supportive care.
Study: NCT06403995

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-referred, undirected Internet-based cognitive behavioral therapy for social anxiety
Description: The Shyness Program is presented in the form of illustrated stories of a working woman and young man with SAD and their health professional (a psychologist). The program comprises six online lessons that teach core cognitive and behavioral principles and skills, including psychoeducation about the symptoms and treatment of SAD (Lessons 1-2); graded exposure and behavioral experiments (Lesson 3); cognitive restructuring (Lessons 4-5); relapse prevention (Lesson 6). The program also includes lesson summaries, homework assignments, and regular scheduled emails to support program users in applying the CBT skills themselves (N. Titov, Andrews, Schwencke, et al., 2008). It is recommended that modules are completed every 1 to 2 weeks with the full program completed within 90 days (see https://thiswayup.org.au/courses/the-social-anxiety-course/).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Recommended, undirected Internet-based cognitive behavioral therapy for social anxiety
Description: The Shyness Program is presented in the form of illustrated stories of a working woman and young man with SAD and their health professional (a psychologist). The program comprises six online lessons that teach core cognitive and behavioral principles and skills, including psychoeducation about the symptoms and treatment of SAD (Lessons 1-2); graded exposure and behavioral experiments (Lesson 3); cognitive restructuring (Lessons 4-5); relapse prevention (Lesson 6). The program also includes lesson summaries, homework assignments, and regular scheduled emails to support program users in applying the CBT skills themselves (N. Titov, Andrews, Schwencke, et al., 2008). It is recommended that modules are completed every 1 to 2 weeks with the full program completed within 90 days (see https://thiswayup.org.au/courses/the-social-anxiety-course/).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Recommended, directed Internet-based cognitive behavioral therapy for social anxiety
Description: The Shyness Program is presented in the form of illustrated stories of a working woman and young man with SAD and their health professional (a psychologist). The program comprises six online lessons that teach core cognitive and behavioral principles and skills, including psychoeducation about the symptoms and treatment of SAD (Lessons 1-2); graded exposure and behavioral experiments (Lesson 3); cognitive restructuring (Lessons 4-5); relapse prevention (Lesson 6). The program also includes lesson summaries, homework assignments, and regular scheduled emails to support program users in applying the CBT skills themselves (N. Titov, Andrews, Schwencke, et al., 2008). It is recommended that modules are completed every 1 to 2 weeks with the full program completed within 90 days (see https://thiswayup.org.au/courses/the-social-anxiety-course/).
Study: NCT04954781

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: Tislelizumab will be initiated on day 14 after the first TACE session. Tislelizumab will be administered at 200 mg i.v. every 3 weeks until documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: TACE
Description: TACE is performed by using drug-eluting beads. TACE treatment starts on day 0. The second TACE will be repeated on day 28 (± 5 days) if necessary per Investigator's decision.
Study: NCT05016921

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TcMS
Description: Transcutaneous magnetic stimulation targeting the stellate ganglion
Study: NCT06013540

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: TAM formula (hydroquinone 2%, tretinoin 0.05% and 5% vitamin C)
Description: TAM formula (hydroquinone 2%, tretinoin 0.05% and 5% vitamin C)

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Kligman formula (hydroquinone 4%, fluocinolone acetonide 0.01% and tretinoin 0.05%)
Description: Kligman formula (hydroquinone 4%, fluocinolone acetonide 0.01% and tretinoin 0.05%)
Study: NCT02645149

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CDK4/6 and MEK inhibitor
Description: Patients mucosal melanoma and any genetic aberration on NGS testing may receive ribociclib + trametinib initially. After failure of trametinib and ribociclib, actionable genetic aberrations from the NGS testing will be reviewed for the opportunity to use a further targeted therapy off label.~Patients with an NRAS mutation on standard of care tumour testing will also receive ribociclib + trametinib.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CDK4/6 and MEK inhibitor
Description: Patients mucosal melanoma and any genetic aberration on NGS testing may receive ribociclib + trametinib initially. After failure of trametinib and ribociclib, actionable genetic aberrations from the NGS testing will be reviewed for the opportunity to use a further targeted therapy off label.~Patients with an NRAS mutation on standard of care tumour testing will also receive ribociclib + trametinib.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Compassionate Access Targeted Therapy
Description: Patients with non-V600 BRAF, BRAF wildtype and NRAS wildtype melanoma may have an actionable aberration(s) for which there is no current study-specific drug supply. In this scenario, access will be sought for compassionate use of the off label use of the relevant regulatory approved targeted therapy
Study: NCT04787029

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Medical compression stocking (medical device name: mediven Harmony 734 (compression class1 AG armsleeve or with wide(735))
Description: Compression stockings worn on the arm or partial swelling of the hand after trauma or surgery.
Study: NCT06358781

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Whole grain wheat flour
Description: Group A: whole grain flour: 0 g Group B: Whole grain flour: 25 g Group C: Whole grain flour: 50 g Group D: whole grain flour: 100g

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Whole grain wheat flour
Description: Group A: whole grain flour: 0 g Group B: Whole grain flour: 25 g Group C: Whole grain flour: 50 g Group D: whole grain flour: 100g

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Whole grain wheat flour
Description: Group A: whole grain flour: 0 g Group B: Whole grain flour: 25 g Group C: Whole grain flour: 50 g Group D: whole grain flour: 100g
Study: NCT06204094

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: node-sparing short-course radiotherapy
Description: 5Gy\*5d, radiation targeting the tumor bed without irradiating surrounding tumor-draining lymph nodes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab
Description: 200mg intravenous infusion d1 of each cycle\*8cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: 1000mg/m2, PO, BID, d1-14 of each cycle\*8cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: 130mg/m2, intravenous infusion,d1 of each cycle\*8cycles

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TME surgery
Description: laparoscopic or robotic TME surgery for non-cCR patients

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: watch and wait
Description: WW for cCR patients
Study: NCT06327867

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Oro Tracheal Intubation by DL
Description: DL

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Oro Tracheal Intubation by VL
Description: VL
Study: NCT06263751

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product prescription program- NutriConnect Credit
Description: Patient is given $20 credit to their Schnucks (grocery) Rewards account every other week for F\&V shopping. The Rewards credit can be used either through the Schnucks App or in store.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product prescription program- NutriConnect Delivery
Description: Patient receives produce (F\&V) box (equivalent $20 value) delivered to home every other week. The items in the box will be pre-selected by Schnucks and the NutriConnect dieticians.
Study: NCT06544707

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.003% AR-15512
Description: Ophthalmic solution administered via topical ocular instillation
Study: NCT05976763

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Colonoscopy
Description: Undergo colonoscopy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Colonoscopy
Description: Undergo colonoscopy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Colonoscopy
Description: Undergo colonoscopy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biospecimen Collection
Description: Undergo blood sample collection
Study: NCT05715073

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: TeaCrine and Caffeine
Description: Participants will take Teacrine and caffeine then an hour later perform an intense interval exercise protocol followed by cognitive tests.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Caffeine
Description: Participants will take caffeine then an hour later perform an intense interval exercise protocol followed by cognitive tests.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will take the placebo cellulose pill and than an hour later perform an intense interval exercise protocol followed by cognitive tests.
Study: NCT05976763

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT06581094

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: UCII, glucosamine and curcumin
Description: compound capsules twice daily.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules twice daily.
Study: NCT04931355

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: The Acupuncture intervention（Zhongwan、Qihai、Guanyuan、Zhongji、Guilai、Shenshu、Ciliao、Xuehai、Sanyinjiao、Taixi.） will start on the 5th day of menstruation cycle, which will be carried out 1 time per day, at least 5 times a week, lasts for 10-15days. All operations were performed by experienced acupuncturists. After ET, both the control group and the treatment group will be treated with conventionally with no TCM intervention.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Western medicine
Description: Western medicine
Study: NCT06408623

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: chidamide combined with Sintilimab and bevacizumab
Description: chidamide combined with Sintilimab and bevacizumab
Study: NCT05922787

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Reiki
Description: In the study, women received four Reiki sessions once a week for four weeks from the researchers with Usuı Shiki Ryoho Reiki 1
Study: NCT04828447

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Olive Oil
Description: Subjects will be randomized to either high or low dose of olive oil and follow a whole food plant based diet.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Olive Oil
Description: Subjects will be randomized to either high or low dose of olive oil and follow a whole food plant based diet.
Study: NCT04199572

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diclofenac and Paracetamol
Description: analgesic effect of diclofenac along with either Oral versus Intravenous paracetamol versus placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diclofenac and Paracetamol
Description: analgesic effect of diclofenac along with either Oral versus Intravenous paracetamol versus placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diclofenac and Paracetamol
Description: analgesic effect of diclofenac along with either Oral versus Intravenous paracetamol versus placebo
Study: NCT05002855

Intervention type: OTHER
Intervention: Enhanced Recovery After Surgery (ERAS)
Description: Multidisciplinary approach to perioperative care.